Defining New Biology
The Alliance of Mitochondria and the Ubiquitin Proteosome System (UPS)
Our Company
Learn More About Progenra
Progenra is advancing a new class of medicine through Molecular Glues and targeted protein degradation. Our UbiPro™ platform leverages the full power of the ubiquitin system to develop therapies for some of the most challenging diseases.
Innovation
Redefining New Treatment Paradigms
Targeted protein degradation is a disease-agnostic modality fundamentally changing how drugs can work, creating unprecedented opportunities to treat a wide variety of diseases.
Where We Focus
Neurodegenerative Diseases
Cardiovascular Disorders
Metabolic Dysfunction
Aging & Cellular Longevity
Pipeline
Our Pipeline
Progenra Events & Meetings
The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease
Progenra Inc, February 2023 Parkinson’s disease (PD) is the most common neurodegenerative movement disorder. There are no available therapeutics that slow or halt the progressive loss of dopamine-producing neurons, which
Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.
May 2020. Progenra has received new funding for its Michael J. Fox Foundation Therapeutic Pipeline Award, Discovery and Development of Novel Parkin Activators. Progenra’s novel Parkin activator molecules are undergoing
Progenra Scientists publish a chapter in the ACS 2019 Medicinal Chemistry Reviews.
February 2020. Ubiquitin-specific proteases (USPs), the major class of deubiquitinating enzymes, or DUBs, remove conjugated ubiquitin from proteins in cells and in so doing help to regulate the content, location,
Partnership With Progenra
Driven by our powerful and highly productive drug discovery engine, we are delivering a pipeline of first-in-class therapeutics designed to transform the standard of care for patients.
